4 chapters across the catalog
The FDA issued a warning letter to Similasan, leading to the removal of homeopathic eye drops from the U.S. market. The hosts speculate on the timing of this removal relative to reports of "pink eye" symptoms associated with bird flu. They also examine the stock performance of Armata Pharmaceuticals (ARMP), noting its significant decline since going public.
The potential financial burden of 65 million Medicare recipients accessing expensive GLP-1 drugs is estimated to reach hundreds of billions of dollars annually. Concerns are raised that these costs will bankrupt the healthcare system, especially following Oprah Winfrey's recent television special promoting the medications.
Reports of "Narcan parties," where drug users supposedly overdose on purpose to be revived, are dismissed as a PR fabrication designed to boost the stock of companies manufacturing the anti-overdose drug. An ex-firefighter explains that Narcan immediately induces violent withdrawal and vomiting, making the idea of using it for a "party" medically absurd. The surge in Narcan-related news is linked to suspicious trading volumes in pharmaceutical stocks.
Gilead Stock Performance, Insider Trading, HPV Vaccine Comparisons
Gilead Sciences' stock (GILD) saw a significant surge on the Nasdaq, doubling in value between January and July 2012, prior to the official FDA announcement regarding Truvada. This price action has led to allegations of insider trading by those aware of the impending approval. The aggressive push for Truvada is compared to the HPV vaccine mandates, with critics warning that long-term side effects or carcinogenic risks may eventually emerge.
